CONTROL NETs TR: A translational sub-study of CONTROL NETs (“Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study”)

The AGITG-sponsored, investigator-initiated CONTROL NETs is a clinical trial for the treatment of advanced pancreatic neuroendocrine tumours (pNETs) and midgut neuroendocrine tumours (mNETs). It is a non-comparative randomised open label parallel group phase II trial with 2:1 randomisation to PRRT/CAPTEM (experimental arm) vs. PRRT (mNETs control) and CAPTEM (pNETS control).

CONTROL NETs TR exploratory sub-study is a multi-omic assessment of MGMT as a biomarker to predict which patients will benefit from the addition of CAPTEM to PRRT, using samples gathered from participants in the CONTROL NETs trial.